The Health Canada license confirms that the Axonics product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada. Axonics previously received ethics committee approval from the University of Toronto to treat patients in Canada as part of the Company’s post-market clinical follow-up study and anticipates treating patients in Canada in the first quarter of 2017.
Category: Overactive Bladder
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
The Health Canada license confirms that the Axonics product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada. Axonics previously received ethics committee approval from the University of Toronto to treat patients in Canada as part of the Company’s post-market clinical follow-up study and anticipates treating patients in Canada in the first quarter of 2017.